| 000 | 01810 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517120504.0 | ||
| 264 | 0 | _c20170413 | |
| 008 | 201704s 0 0 eng d | ||
| 022 | _a2376-1032 | ||
| 024 | 7 |
_a10.18553/jmcp.2016.22.10-a-s.s3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBowlus, Christopher L | |
| 245 | 0 | 0 |
_aPrimary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update. _h[electronic resource] |
| 260 |
_bJournal of managed care & specialty pharmacy _cOct 2016 |
||
| 300 |
_aS3-S15 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aChenodeoxycholic Acid _xadverse effects |
| 650 | 0 | 4 |
_aCholagogues and Choleretics _xadverse effects |
| 650 | 0 | 4 |
_aCholangitis _xdrug therapy |
| 650 | 0 | 4 | _aCongresses as Topic |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 |
_aDrug Therapy, Combination _xadverse effects |
| 650 | 0 | 4 | _aEducation, Pharmacy, Continuing |
| 650 | 0 | 4 |
_aEnd Stage Liver Disease _xeconomics |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 | _aFormularies as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInsurance Coverage |
| 650 | 0 | 4 | _aInsurance, Pharmaceutical Services |
| 650 | 0 | 4 |
_aLiver Transplantation _xadverse effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrescription Fees |
| 650 | 0 | 4 |
_aRare Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aReceptors, Cytoplasmic and Nuclear _xagonists |
| 650 | 0 | 4 | _aSatellite Communications |
| 650 | 0 | 4 |
_aUrsodeoxycholic Acid _xadverse effects |
| 700 | 1 | _aKenney, James T | |
| 700 | 1 | _aRice, Gary | |
| 700 | 1 | _aNavarro, Robert | |
| 773 | 0 |
_tJournal of managed care & specialty pharmacy _gvol. 22 _gno. 10-a-s Suppl _gp. S3-S15 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18553/jmcp.2016.22.10-a-s.s3 _zAvailable from publisher's website |
| 999 |
_c26481723 _d26481723 |
||